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ABSTRACT 
Quadruplex-forming sequences are widely prevalent in human and other genomes, including 
bacterial ones. These sequences are over-represented in eukaryotic telomeres, promoters and 
5' untranslated regions. They can form quadruplex structures, which may be transient in many 
situations in normal cells since they can be effectively resolved by helicase action. Mutated 
helicases in cancer cells are unable to unwind quadruplexes, which are impediments to 
transcription, translation or replication, depending on their location within a particular gene. 
Small molecules that can stabilise quadruplex structures augment these effects and produce 
cell and proliferation growth inhibition. This article surveys the chemical biology of 
quadruplexes. It critically examines the major classes of quadruplex-binding small molecules 
that have been developed to date and the various approaches to discovering selective agents. 
The challenges of requiring (and achieving) small-molecule targeted selectivity for a 
particular quadruplex are discussed in relation to the potential of these small molecules as 
potentially clinically-useful therapeutic agents.   
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INTRODUCTION 
    The concept that certain guanine-rich nucleic acid sequences can form four-stranded 
structures is now over fifty years old, although the knowledge that such sequences form 
aggregates is much older.1 Initially fibre-diffraction studies2-4 were used to establish that 
polymeric runs of guanylic acid (and also guanosine monomers) form right-handed four-fold 
helices, and proposed that the strands are tightly held together by guanine-guanine Hoogsteen 
hydrogen-bonding to form guanine base quartets (termed G-quartets or G-tetrads: Figure 1a). 
the quartets stack together in the manner of base pairs in duplex nucleic acids, with the 
striking differences of having four strands, and sodium or potassium ions held centrally 
between quartets and coordinated to the O6 substituent of a guanine base.5  
     It was subsequently found that such guanine-rich sequences form the underlying repeat 
motif of telomeric DNA at the ends of all eukaryotic chromosomes6-8 and also that short-
length oligonucleotides containing such sequences can form discrete structures, termed 
quadruplexes9 (Figure 1b). These structures can be formed10-12 from  
(i) a single strand, folded back three times (unimolecular quadruplexes), having the 
general sequence Ga Xn Gb Xo Gc Xp Gd where Ga-d represent short guanine (G) 
tracts and Xn-p represent intervening “loop” regions of more general length and 
sequence 
(ii) two strands, which are normally identical (bimolecular quadruplexes), each folded 
back once  
(iii) three13 or four strands (tetramolecular quadruplexes).  
     Quadruplexes can adopt a wide diversity of structures and topologies (outlined below), in 
striking contrast to the relative uniformity of duplex nucleic acids. A number of quadruplexes 
have been characterised by biophysical methods, especially by circular dichroism and 
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fluorescence spectroscopy.14,15  All have the common feature of a core of stacked G-quartets, 
a central ion channel and four grooves, of varying dimensions (Figure 2a,b). The diversity 
arises in particular from (i) the variability of loop length and sequence, (ii) sequences in 
which the length of G-tracts is non-equivalent, and (iii) the influence of monovalent ions in 
the channel. Quadruplexes remained of little more than academic interest, until the early 
1990s, when several seminal NMR16-18 and X-ray crystallographic19 studies confirmed the 
earlier supposition of the nature of the G-quartet and its role as the underlying structural 
motif in quadruplexes.  
    This article will discuss the background to, and current status of quadruplexes, 
emphasizing their targeting with small molecules for therapeutic ends. It will also examine 
some future directions for this rapidly-developing field, including structure-based approaches 
and their relevance to the development of new therapeutic agents. The interested reader is 
referred to the large number of existing reviews on various other aspects of quadruplex 
chemistry, biophysics and biology for further background reading.10-12,14-15,20-24   
QUADRUPLEX PREVALENCE AND STABILITY  
     The determination of the sequence of the human genome (comprising ca three billion 
nucleotides) in 2002 led to the discovery of the wide prevalence of putative quadruplex 
sequence motifs,25-29 in addition to their inherent occurrence in human telomeric DNA (see 
below). The initial search algorithms employed in two independent informatics studies25,26 
both used a basic search sequence of G3-5 Xn G3-5 Xo G3-5 Xp G3-5, albeit with distinct 
algorithms. Both assumed that loops Xn, Xo and Xp would have 1-7 nucleotides, and that the 
size of the G-tracts varied between three and five guanines in length, but that they were not 
necessarily of equal length. The loop length limits were set on the assumption that shorter 
loops would be of greatest stability, in accordance with experimental and computational 
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studies.30-32 Both these studies independently resulted in the finding of ca 350,000 putative 
occurrences, of which a significant number occur in longer stretches of multiple G-tracts 
(“quadruplex islands”), where the definition of an individual quadruplex may be ambiguous 
and thus there is likely to be multiple and overlapping quadruplex species. The existence of a 
stable quadruplex can be validated by the combined use of several spectroscopic and 
biophysical techniques, notably UV fluorescence33 and circular dichroism,34 optimally 
together with X-ray crystallographic35 and NMR analyses.36  
     The concept that individual loops within a stable genomic quadruplex cannot contain more 
than seven nucleotides has been more recently challenged by experimental findings of 
quadruplex-forming sequences with long loops in a number of quadruplexes. Examples 
include:  
(i) a nine-nucleotide propeller loop determined in the NMR structure of a quadruplex 
within the human CEB25 mini-satellite locus, which comprises almost perfect 52-
nucleotide tandem repeats.37  
(ii) A 26-nucleotide loop, stabilised as a hairpin and with C:G and G:G base pairing, has 
been reported to be formed within a quadruplex encoded in the promoter sequence of 
the hTERT gene.38  
(iii) Very long central loops have been identified using a combined bioinformatics and 
experimental  approach in the 5'-UTRs (untranslated regions) of human mRNAs, 10-
90 nucleotides in length and with each flanking loop comprising just a single 
nucleotide.39  
(iv) An NMR study has shown that the promoter of the human BCL-2 gene contains a 13-
nucleotide central loop,40 of sequence d(CGCGGGAGGAAGG). 
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    These results strongly suggests that the original loop length definitions25,26 are too 
restrictive, and that the total number of putative quadruplexes is much greater than the 
original tally of ca 350,000. This is also in accord with a systematic experimental study of 80 
different sequences,41 which concluded that provided the flanking loops are short, then a very 
long central loop can be tolerated. The ability of this loop to form stable secondary 
interactions is clearly a major factor in determining stability. Shorter loops can also do this: 
the five-nucleotide lateral loop of sequence d(AGGAG) in the promoter of the c-KIT gene 
forms a highly stable secondary structure with two G:A base pairs, as observed in 2D-NMR42 
and crystal structures,43,44 and persists in molecular dynamics simulations.44,45 Although 
detailed structural data on the 13-nucleotide loop in the BCL-2 promoter quadruplex40 is not 
yet available, its sequence is strongly suggestive of it also containing a number of stabilising 
G:A base pairs.  
      The effects of longer loop length are however not straightforward and ultimately depend 
on the sequence of the loop(s) and possibly on the biological function and sequence context 
of the quadruplex. This has recently been illustrated in the case of the quadruplex sequence in 
the human mini-satellite 39-nucleotide CEB25 repeating motif, with a 9-nucleotide central 
loop flanked by two single-nucleotide T loops.37 The overall quadruplex sequence is 
d(GGGTGGGTGTAAGTGTGGGTGGG). Although this central loop (shown in bold) 
appears to be much less structured than the long loops in other quadruplexes in for example 
the BCL-2 or c-KIT genes, its presence still imparts some stability to this quadruplex. A 
subsequent detailed analysis46 of the effects of varying loop length both in vitro and in vivo 
on the CEB25 mini-satellite in Saccharomyces cerevisiae cells has revealed that the length of 
the central loop is an important factor in determining genomic instability at such sequences. 
Short (≤ 4 nucleotide) central loop CEB25 quadruplexes have enhanced stability compared to 
ones with a longer loop and can act to block replication and enhance genomic instability. 
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      The overwhelming majority of quadruplex studies, especially those related to small-
molecule therapeutics, have focussed on the human genome. Putative quadruplex-forming 
sequences have been located using bioinformatics approaches in a number of organisms other 
than homo sapiens (there is frequently strong evolutionary conservation of quadruplex motifs 
in vertebrates,47 for example between canine and humans in the c-KIT gene48). Examples of 
other organisms with quadruplex-containing genomes include Saccharomyces cerevisiae,49 
Escherichia coli
50,51 and a large number of bacterial species.52 In broad terms the effects of a 
quadruplex sequence on transcription and translation depend on its position within an E. coli 
gene.50 A number of quadruplex-forming sequences have been identified within the HIV 
genome, including within the long terminal repeat (LTR) promoter53,54 and in the coding 
region of the NEF gene.55 Therapeutic implications of targeting these HIV quadruplexes are 
discussed below. Potential quadruplex-forming sequences have also been located in the small 
(23 million nucleotide) malaria genome,56 with 63 non-telomeric quadruplexes being 
identified in this genome using a search sequence containing up to 11 nucleotides in the 
loops. Of these, 16 are clustered upstream of var genes, and there is some evidence that 
several of these quadruplexes can be selectively targeted in vitro,56 as demonstrated with a 
synthetic macrocyclic dibenzophenanthroline derivative.  
       The development of methodology to directly locate genomic quadruplex occurrences 
using a combination of next-generation sequencing and the polymerase stop assay has 
recently been applied to the human genome.57 Results were consistent using either K+ ions or 
stabilising ligands to induce quadruplex formation, and a large number of previously known 
quadruplex-forming regions have been identified and validated. In addition, and 
unexpectedly, quadruplexes were found in genes which had previously not been identified by 
computational search methods:25,26 two such notable genes are the breast cancer susceptibility 
genes BRCA1 and BRCA2. Overall, a total of 716,310 quadruplex occurrences were 
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identified, of which 451,646 had not been previously predicted. Many of these have non-
canonical quadruplex structures (ie they do not conform to the G3-5XnG3-5XoG3-5XpG3-5 
pattern of quadruplex sequence norm) and/or long loops. Of particular relevance to potential 
drug targeting was the prediction of regions of high quadruplex density within oncogenes 
such as c-MYC and BCL-2. 
       Direct experimental observations of quadruplexes in cells have relied on the generation 
of quadruplex-specific antibodies, which were first successfully applied58 to demonstrate the 
presence of quadruplexes in the transcriptionally active macronuclei of the ciliate organism 
Stylonychia lemnae. Interestingly, no evidence of antibody staining was found in the 
replication region of this organism; this prescient finding was suggested as indicative of 
quadruplexes being resolved (ie unwound) during replication. Another antibody, also with the 
ability to specifically pull-down quadruplex nucleic acid structures has been developed more 
recently59 for use with human cells, initially with MCF-7 breast carcinoma cells, in tandem 
with deep sequencing, to map the occurrence of quadruplexes in the genome for this cell line. 
Quadruplex signals were found to be enriched in particular, in sub-telomeric and regulatory 
regions. Furthermore a representative set of enriched genes are sensitive to transcriptional 
down-regulation when treated with the quadruplex-specific ligand pyridostatin (1). Direct 
visualisation of quadruplex occurrence within (fixed) cancer cells has been demonstrated 
using the antibody approach coupled with fluorescent probes.60,61 Interestingly the images 
show finite numbers of quadruplex foci, strongly suggesting that the number of stable 
quadruplexes within these cell lines is not large. One of these antibodies60 (BG4) has been 
used to examine quadruplex occurrence in human tissues and elevated levels have been found 
in patient-derived stomach and liver cancers, contrasting with lower responses in normal 
tissues.62 Possible causes of these elevated quadruplex levels are discussed further below, but 
Page 7 of 93
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
8 
 
this data overall is strongly suggestive of underlying differences in actual quadruplex 
occurrence between normal and cancer cells.  
     Antibody-based quadruplex visualisation is restricted to fixed or permeable cells and 
tissues, and thus may potentially be prone to artefacts arising from the fixing process. Several 
groups are developing small-molecule quadruplex-specific probes that are useable in live 
cells. These show significant differences in fluorescent emission/excitation maxima and 
especially in fluorescent decay lifetimes when bound to quadruplex versus other types of 
nucleic acids. Examples include 3,6-bis(1-methyl-2-vinylpyridinium) carbazole diiodide63 (o-
BMVC: 2), naphthoTASQ (a G-quartet mimetic tetra-substituted naphthalene derivative,64 3) 
and a planar triarylmethyl carbocation65 (4). These promising approaches will need cross-
validation with quadruplex-binding antibodies before they become generally useable. At 
present neither the antibody nor the small-molecule visualisation methodology is able to 
identify an individual quadruplex within a genome, although this may be more readily 
feasible with a small genome such as that of HIV, which has only a small number of 
quadruplex targets.  
TELOMERIC QUADRUPLEXES 
The ability of eukaryotic telomeric sequences DNA, and in particular human telomeric DNA 
based on the hexanucleotide repeat sequence d(TTAGGG),8,66 to form discrete quadruplex 
arrangements,6,7,9,66,67 requires a transient or stable single-stranded stretch of DNA. Typically 
telomeric DNA can range in length from 3-7 kilobases, almost all of which except the 
extreme 100-200 nucleotides at the 3' end,68 is double-stranded. This single-stranded 
overhang, free from the constraints of Watson-Crick base pairing, is thus in principle 
available for quadruplex formation and indeed such structures will spontaneously form in the 
absence of associated proteins. Telomeric duplex DNA may be folded into a higher-order 
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structure (the t-loop), and is associated with an array of telomere-binding proteins (TRF1, 
TRF2, RAP1, TIN2, and TPP1), collectively termed the shelterin complex.69 The single-
stranded overhang is also not normally free to form higher-order structures since it is 
associated with a number of copies of the single-strand telomere binding protein POT1 
(hPOT1 in humans).70 This protein thus effectively destabilises quadruplex formation at 
telomeric DNA ends.71 The shelterin complex is involved in telomere length regulation, and 
POT1 is involved in telomere end-protection via feedback to other telomeric proteins within 
the shelterin complex, notably TIN2 and TRF2.72  
     The discovery of the telomere length maintenance enzyme telomerase73 and its 
identification as a specialised reverse transcriptase, was followed in the mid-1990s by the 
finding of a profound link between the up-regulated expression of telomerase and 
oncogenesis.74,75 This has been the starting-point for the surge of interest in telomeric 
quadruplexes, and ultimately in quadruplexes generally as therapeutic targets. The detailed 
chemistry at the telomerase catalytic sub-unit (hTERT in humans) active site involves 
assembly of nascent telomeric DNA onto the 3´ end telomeric DNA end. The process occurs 
on a complementary RNA template (hTR) and uses a pool of precursor mononucleotide 
triphosphates, with its substrate, the 3´ end of telomeric DNA, hybridising onto the template, 
and so the telomeric DNA must be single-stranded at this point. The enzymatic activity of 
hTERT can be inhibited by sequestration of this 3´ single-stranded end into a quadruplex 
arrangement76, which is augmented by the stabilising influence of a quadruplex-binding small 
molecule.77 Quadruplex formation in the telomeric DNA substrate effectively hinders this 
hybridisation from occurring. This approach to telomerase inhibition has been subsequently 
developed into an anti-cancer strategy78-81 following proof-of-principle experiments 
demonstrating in general that inhibition of telomerase function in tumour cells (where its 
expression is up-regulated in ca 80-85% of all human cancers) leads to senescence and 
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apoptosis. These key experiments used antisense oligonucleotides,82 dominant-negative 
mutants of the catalytic domain of telomerase83 or hTERT catalytic-site small-molecule 
inhibitors.84 The onset of replicative senescence normally requires telomeric DNA to shorten 
to a critical length and is accompanied by up-regulation of the RB pathway85,86 via the cyclin-
dependent kinase inhibitor p21, and increased expression of the tumour suppressor protein 
p16INK4a.  This leads to senescence induction, which is a precursor to selective cancer cell 
apoptosis and cell death. These cellular and molecular events have also been observed in 
cellulo with a number of quadruplex-binding small molecules, as well as demonstrating 
telomerase inhibitory activity and telomere shortening. Examples of telomeric quadruplex-
binding agents (Figure 3) include quinoline-based triazine compounds (5),87 BRACO-19 (6: 
an acridine derivative88,89), the perylene derivatives PM2 and PIPER (7)90 and more recently, 
a ruthenium complex with chiral 4-(2,3-dihydroxypropyl)-formamide oxoaporphine.91 The 
consequences of what is now termed telomere targeting with be discussed further in a 
subsequent section. 
      The unexpected findings92-94 that telomeric DNA can be transcribed into discrete (non-
coding) telomeric RNA molecules, termed TERRA, may indicate further potential targets for 
small-molecule quadruplex-mediated intervention at the telomere since TERRAs readily 
form stable RNA quadruplexes.95-98 TERRA molecules are involved in regulating telomere 
length, via telomerase activity in telomerase-positive cancer cells, and also form TERRA 
RNA-telomeric DNA hybrids, which may be involved in recombination-mediated telomere 
length homeostatis in telomerase-negative ALT cell types.99,100 TERRA molecules also play a 
role in the DNA damage response at telomeres.101 It is not clear at present what, if any role, 
natural TERRA quadruplexes might play in these processes, so stabilising them with small 
molecules may or may not have therapeutic benefit in proliferating cells. 
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Quadruplex-mediated targeting of telomerase and telomere maintenance. The finding 
that a disubstituted amidoanthraquinone compound (8) could inhibit the catalytic action of 
telomerase from elongating the 3' single-stranded end of telomeric DNA, was correlated with 
its ability to fold the end into a quadruplex arrangement.77 Subsequent synthesis and 
evaluation of the regioisomeric series of bis-amidoanthraquinones enabled structure-activity 
relationships to be established, which strengthened the evidence for a causal link between 
binding and activity.102-104 The overall structural features needed for effective small molecule 
binding to a quadruplex and optimal telomerase activity within a series are closely similar 
and have been defined as (i) the possession of an extended heteroaromatic chromophore 
which can π-π stack onto a G-quartet surface of aquadruplex, and (ii) normally (at least) one 
flexible side-chain containing terminal cationic-charged moiety such as a pyrrolidine or 
piperidine group. The chemical space for quadruplex-binding telomerase-inhibiting 
compounds has been subsequently extended to a large number of chemotypes. These are 
mostly based on polyheteroaromatic compounds, for example the tetra-N-methylpyridyl-
porphyrin compound (TMPyP4: 9, well-studied but non-selective),105 a series based on the 
pentacyclic dibenzophenanthroline core,106 the N,N'-bis[2-(1-piperidino)ethyl]-3,4,9,10-
perylenetetracarboxylic diimide PIPER107 and a pentacyclic acridinium compound (RHPS4, 
8,13-diethyl-6-methylquino[4,3,2-kl]acridinium iodide: 10) and dervivatives.108  
      The concept of using substituted polycyclic and heteroaromatic compounds as probes 
(and potential anticancer leads) has been the dominant theme in the subsequent development 
of the majority of quadruplex-binding ligand libraries, whether targeted to telomeric or other 
categories of quadruplex.20,22,109,110 Some of these libraries are derived from natural products, 
such as the core chromophores of the alkaloids berberine (11) and quindoline (12), but the 
majority are purely synthetic in origin. In addition, a number of categories of transition metal-
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containing complexes have been developed to target telomeric quadruplexes,111 some of 
which are also potent telomerase inhibitors (see for example.112, 113) 
      Notable exceptions to the polycyclic + cationic substituted side-chain class are 
compounds based on, or derived from the macrocyclic natural product telomestatin (13), 
which comprises five unsubstituted oxazole rings, two methylated oxazole rings and a 
thiazoline ring with one asymmetric centre.114,115 Even though (13) has no formal positive 
charge and the molecule is slightly non-planar, its extensive π-π overlap with a terminal G-
quartet in quadruplexes116 confers high affinity and selectivity, low duplex affinity, and is 
combined with potent telomerase inhibitory ability. However (13) is highly insoluble in 
aqueous media and thus challenging to formulate for biological studies or potentially as a 
therapeutic agent. A number of (13)-mimetic macrocyclic scaffolds have been reported117, 
often comprising a number of oxazole rings interspersed with for example, pyridyl and/or 
phenyl rings or amide groups (for example, 14).118 These linked rings may form a fully cyclic 
system, as in (13) itself, or may be open, forming a three-sided or acute crescent-like shape, 
with an angle of ca 90° between each arm. The ubiquitous alkylamino type of cationic side-
chain has been added to several of these ring systems, notably in derivative of the compound 
HXDV,119 which has six linked oxazole rings and two valine units together with a 
dimethylaminoalkyl side-chain. A number of these compounds show high potency (<1 µM) 
in cell proliferation assays together with effective quadruplex stabilising properties. One 
compound (15) in this series has been evaluated in the MDA-MB-435 breast tumour 
xenograft model with evidence of diminished tumour growth relative to controls, although 
the relationship of the in vivo activity to quadruplex binding has yet to be elucidated. 
       The classic model of senescence and apoptosis induction via telomerase inhibition 
requires that telomere shortening occurs in a timely manner, progressing through to the limit 
of telomere length attrition (for example in MCF-7 human breast carcinoma cells, which have 
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a mean telomere length of ~6 kilonucleotides). Since ~100 nucleotides are lost per round of 
replication, critical senescence events should only be activated after a large number of rounds 
of replication.120,121 Although several early studies on quadruplex-binding small molecules 
did observe progressive telomeric DNA shortening,87,90 senescence and growth arrest 
occurred much more rapidly than predicted on the basis of the classic senescence model of 
critical telomere shortening being required. Rapid inhibition of cell growth and proliferation 
was also accompanied by changes at the telomere itself such as anaphase bridge formation 
and end-to-end chromosomal fusions. These changes are consistent with telomere end 
uncapping from associated proteins88,90,122-4, including hPOT1, which binds to the single-
stranded overhang70 and is known to be displaced by quadruplex formation.71 It has been 
suggested that the telomerase enzyme complex is physically associated with the extreme 3' 
end of the telomeric DNA overhang in cancer cells, with the inference that this association is 
displaced on quadruplex formation,125  and thus telomere attrition is no longer the rate-
determining event. These rapid senescence- and apoptosis-inducing effects have subsequently 
found to be induced by almost telomeric quadruplex-binding small molecules. Ligand-
induced quadruplex stabilisation and telomere uncapping also results in DNA damage to 
telomeres and consequently initiates a cascade of responses with altered regulation of, in 
particular, p21/p16INK4a kinases, p53, PARP and ATM/ATR pathways. The DNA damage 
responses are characterised by senescence126 and the rapid appearance of phosphorylated 
histone γ-H2AX foci, often being apparent 24 hrs after compound administration.127 These 
responses have been studied in detail with several quadruplex-binding small molecules, 
notably with the pentacyclic acridine derivative (10),128-130 the macrocycle (13)131 and the 
bis(quinolinyl)pyridine-dicarboxamide derivative (1).127 There is also evidence that the 
observed antitumour activity of (10) in xenograft models is a direct consequence of the 
critically-important DNA damage response.128 Intriguingly, a study of the effects of (1) on 
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the genome of several cancer cell lines using a chromatin immunoprecipitation sequencing 
approach132 has revealed that this compound (which has high quadruplex-specificity and very 
low duplex DNA affinity133), produces DNA damage at both telomeres and a small number 
of non-telomeric regions of the genome, notably at the SRC gene locus. 
           The classic model of quadruplex-induced telomerase inhibition and telomere length 
attrition by small molecules with affinity for telomeric quadruplexes has evolved into a more 
direct mechanism in cancer cells, leading directly to telomere-induced senescence, growth 
inhibition and apoptosis. The telomere maintenance effects of these compounds involve 
telomere uncapping and induction of telomere damage, and telomerase inhibition, though it 
may well still play a role, does not appear to be the major factor. Selectivity for cancer cells 
may be a consequence of deficiencies of the DNA damage response apparatus in many 
cancers.134 Initial events are the dissociation of hPOT1 from the single-stranded overhang and 
possibly the uncapping of telomerase from telomere ends to enable quadruplex formation, 
which then acts as a damage-response signal. Once formed, quadruplexes need to be rapidly 
unwound otherwise they pose an impediment to the normal functioning of a cell. The helicase 
RTEL1 provides an additional defence to telomere targeting by quadruplex stabilisation since 
it is able to effectively unwind telomeric quadruplexes and thus maintain telomere 
integrity.135 In those instances where telomere dysfunction via small-molecule quadruplex 
binding has been unequivocally validated, it is a reasonable assumption that RTEL1 itself has 
also been disabled.  The recent finding of a non-uniform distribution of quadruplexes within 
cell nuclei and preferential localisation in heterochromatin136 has been suggested to be a 
consequence of the molecular crowding within heterochromatin, and also implies that 
epigenetic factors may play a role in selectivity.  
         It should not be assumed that strong ligand binding to human telomeric quadruplexes in 
vitro means that the cellular (and in vivo) mechanism of action involves telomere 
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maintenance dysfunction – other quadruplexes may be more significant targets in particular 
cell types. The available evidence points to telomere targeting being the critical mechanism 
of action for at least one well-characterised example, the acridines-based compound (10). 
However the increasing application of high-definition genomic probes, (with (1)132 being a 
prominent example) is demonstrating an altogether more complex scenario, in view of the 
multiplicity of non-telomeric quadruplex sites in the human genome, as discussed in the next 
section.  
PROMOTER QUADRUPLEXES 
In parallel with the developing interest in telomeric quadruplexes in the 1990s, potential 
quadruplex arrangements began to be identified in a variety of genomic contexts and genes, 
initially in retinoblastoma susceptibility genes137 and notably, in the nuclease hypersensitive 
element within the promoter of the c-MYC gene.138-140 The occurrence of a quadruplex 
sequence in the promoter region of a particular gene (with c-MYC being the paradigm for 
many subsequent studies) has been developed into a second potential therapeutic quadruplex-
targeting strategy in human cancers.140,141 The concept was initially articulated as a simple 
inhibition of function following the induction of a stabilising quadruplex-small molecule 
complex (using the porphyrin compound (9)).140 It has received much attention and a number 
of genes with putative promoter quadruplex sequences have been subsequently identified, 
initially by a bioinformatics approach.142-144 A quadruplex-small molecule complex would be 
an effective impediment to RNA polymerase transcription. Subsequent validation of a 
particular sequence as being capable of forming a stable quadruplex has in large part come 
from biophysical studies. Typically this has involved the application of circular dichroism, 
fluorescence and NMR spectroscopy to isolated quadruplex sequences. Promoter 
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quadruplexes have also been identified in bacterial genomes,145 although here as yet the 
concept has not been significantly exploited to date. 
     The majority of stable promoter quadruplexes reported are from human oncogenes and 
cancer-associated genes, and all appear to be intramolecular. In a number of instances the 
sequences are within established nuclease hypersensitive/transcriptional activation sites 
within or upstream of promoter regions. Well-studied examples of genes containing such 
quadruplex sites for which quadruplex formation in vitro has been demonstrated include c-
MYC,140 BCL-2,40,146 h-RAS147, k-RAS,148 c-KIT,149,150 HIF,151,152 b-RAF,153,154 the androgen 
receptor,155 RET,156,157 HSP90,158 MET159 and VEGF,160 whereas promoter quadruplexes 
appear to under-represented in genes associated with normal cellular processes. Many 
validated and putative promoter quadruplexes tend to be within 1kb, more commonly 
immediately upstream and close to the transcription start site in these genes. Perhaps 
unsurprisingly they can also include or are overlapping with the G-rich SP1 transcription 
factor binding sites161 d(GGGCGG), which would serve to augment their ability to repress 
transcription. Some of these genes, which are over-expressed in particular cancers, have been 
targeted with small molecules at the protein level and in several instances, compounds are in 
the clinic (for b-RAF, c-KIT) or in clinical trial (for example for MET, BCL-2). However 
several of the proteins encoded by genes in this list have long been considered to be 
undruggable – c-MYC and the RAS proteins are prominent examples. Quadruplex targeting 
at the gene level, at least in principle, offers the possibility of circumventing such roadblocks. 
      In striking contrast to the relative simplicity of human telomeric quadruplexes, where the 
quadruplex unit is four d(TTAGGG) repeats, many promoter quadruplexes have complex 
sequences. There high diversity in overall sequence, as would be expected, which translates 
into diversity in the nature of the G-tract size and in the size and sequence of the loops. Some 
quadruplexes unequivocally comprise just four G-tract repeats, notably the two quadruplexes 
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in the c-KIT gene,149,150 which are 22- and 21-mers respectively. These are between -87 and -
109 bp and between -140 and -160 bp upstream of the transcription initiation site. The latter 
is adjacent to the SP1 transcription factor binding site. By contrast, the well-studied 27-mer 
NHE III1 element of the c-MYC promoter contains five short G-tracts, and that both four-tract 
quadruplexes (1234- and 2345-G-tract) can be formed,162,163 and indeed a quadruplex can be 
formed with all five tracts.164 The major quadruplex-forming sequence in the BCL-2 promoter 
is a 39-mer with six G-tracts, so that in principle up to 15 distinct four-tract intramolecular 
quadruplexes are possible. Unsurprisingly, quadruplexes formed from such clusters can be 
conformationally complex, although when several loops are short (each with ≤ two 
nucleotides), then individual quadruplexes tend to have parallel folds. This is the case even 
when one loop is long, as with a BCL-2 quadruplex.40 Cell-based experiments have shown 
that the promoter of the SRC proto-oncogene is a major binding site for the well-studied 
quadruplex-selective compound (1).132 This site has six G-tracts, suggesting that these 
enhanced quadruplex clustering are possible hot-spots for quadruplex-binding small 
molecules, although in this study not all such sites were targeted, as judged by DNA damage 
responses.      
     The promoter of the hTERT gene (the catalytic domain of the telomerase complex) is 
mutated in a number of human cancers,165 notably in melanomas and gliomas, leading to 
enhanced expression of telomerase and maintenance of the malignant phenotype in these 
cancers. The mutations occur in a highly distinctive putative quadruplex-forming region38 
with 12 G-tracts. The topology of a major quadruplex formed in this region is currently 
controversial, with one model based on foot-printing analysis having a 26-nucleotide loop, 
contrasting with NMR studies on one segment of the sequence having a parallel and a (3+1) 
hybrid quadruplex in equilibrium.166 Biophysical and simulation studies167 on the complete 
Page 17 of 93
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
18 
 
hTERT G-tract region suggest the possibility of a complex arrangement involving three 
stacked parallel quadruplexes, but with some cross-interaction between them.   
Promoter quadruplex targeting with small molecules. The early demonstration of c-MYC 
down-regulation by a small molecule has prompted much effort to target this and a number of 
other quadruplexes, with a view to eventual therapeutic utility. A few examples are given 
here. Substituent groups are usually flexible acyclic chains terminating in cationic groups.  A 
persistent challenge is that even if strong binding to a particular promoter quadruplex is found 
in vitro and effects consistent with down-regulation of the target gene in cells are observed, 
this does not necessarily constitute robust validation of the cellular effects being direct on-
target ones. However evidence of down-regulation at both mRNA and protein levels is 
usually taken to be highly suggestive of on-target effects, and such evidence has been 
documented in a number of instances 
     BCL-2 expression has been shown to be down-regulated, for example, by members of a 
small library of mono-substituted quindoline (12) derivatives,168 using a luciferase reporter 
assay to select compounds with optimal promoter quadruplex stabilising ability. BCL-2 
expression was down-regulated at the mRNA level and reduced levels of BCL-2 protein were 
also observed following cell treatment with the most effective BCL-2 quadruplex binder in 
the series. BCL-2 expression was also shown to be down-regulated in MIA-PACA2 
pancreatic cancer cells169 and tumour xenografts170 treated with the tetra-substituted 
naphthalene diimide compound MM41 (16). This compound has exceptional affinity for 
several quadruplexes, especially human telomeric and BCL-2 promoter ones. Selectivity at 
the cellular level was indicated on the basis of BCL-2 mRNA levels being selectively down-
regulated in several pathway-focussed PCR gene arrays (for oncogenes, DNA damage 
response and for telomere maintenance-related genes). However BCL-2 down-regulation was 
not the sole significant gene change observed, suggesting that with this compound in this 
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particular cell line there are likely to be several major quadruplex targets. Thus protein levels 
of both BCL-2 and k-RAS were reduced in treated tumours compared to controls – k-RAS 
mutation and dysregulation is a key driver of most pancreatic cancers and cell lines. 
Comparisons of changes in gene expression in short-term cell culture conditions with those in 
long-term treated tumours need to be made with caution since in the latter such effects may 
be masked by or mistaken for global necrotic and apoptotic effects. A study of gene 
expression changes induced by a trisubstituted naphthalene diimide derivative (17), also 
using a focussed gene array approach, has similarly observed BCL-2 as well as hTERT 
mRNA down-regulation in several cancer cell lines including a melanoma one.171 In accord 
with other observations,169,170 no reduction in c-MYC expression was observed, which is 
notable in view of the ubiquitous role of c-MYC in oncogenesis and the ability of this and 
many other such small molecules, to bind with high affinity to c-MYC quadruplexes. The 
array data derived from this trisubstituted naphthalene diimide indicates that in some cell 
lines at least the pattern of modulation of gene expression correlates with putative quadruplex 
potential, although the small number of genes surveyed probably preclude a more definitive 
conclusion.   
      The two quadruplexes found in the promoter of the c-KIT oncogene can been stabilised 
by a variety of polycyclic-based small molecules, including substituted indenoisoquinolines, 
tri-substituted isoalloxazines and mono-substituted benzo[a]phenoxazines.172-174 A target 
validation study has been reported174 employing a 173-member compound library including 
mono-substituted benzo[a]phenoxazines (18), using a luciferase reporter assay approach, 
established in the human HGC-27 gastric cancer cell line with and without c-KIT promoter 
quadruplex formation. This enabled the assignment of quadruplex-related effects to be made 
with confidence. The two hit compounds from this assay showed dose-dependent reduction 
of c-KIT expression in HGC-27 cells. 
Page 19 of 93
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
20 
 
       The reality of small molecule-driven promoter quadruplex transcriptional down-
regulation is likely to be considerably more complex than the straightforward picture outlined 
above and may well also involve small-molecule interactions with the opposite i-motif strand 
in a quadruplex-containing duplex sequence, as well as proteins such as nucleolin that would 
stabilise a quadruplex complex once formed. Discussion of these topics is beyond the scope 
of this review and the reader is referred to, for example, recent mechanistic studies on small 
molecule binding to the BCL-2 and c-MYC promoter loci.175-177  
     A number of studies have reported high affinity of a small molecule (often a quindoline 
derivative) to a particular promoter quadruplex, together with observations of down-
regulation of the gene, sometimes at both mRNA and protein level. The dangers of assuming 
a direct cause and effect relationship between in vitro and cellular observations have been 
well illustrated by a structure-activity study on the effects of 11-piperazinylquindoline 
derivatives, such as (2-(4-(10H-indolo[3,2-b]quinolin-11-yl)piperazin-1-yl)-N,N-
dimethylethanamine: 19) on c-MYC expression.178 Several compounds in this series are 
effective stabilisers of a c-MYC quadruplex. The lead compound inhibits cell growth and 
produces c-MYC down-regulation in cells; several other derivatives also have effects on other 
quadruplex-containing genes, as well as their quadruplexes. An exon-specific assay,179 which 
is an elegant alternative to using a pair of isogenic cell lines, exploits particular translocation 
features of the CA46 Burkitt’s lymphoma cell line and was used to demonstrate178 that c-
MYC quadruplex targeting is not directly involved in c-MYC down-regulation by this 
compound. However indirect effects on “quadruplex target” genes are not by any means 
universal and appear to depend on the nature of the small molecule involved, and on the cell 
type. For example, and in striking contrast to the study outlined above,178 an ellipticine 
derivative with a single dimethylaminoethoxy side-chain (GQC-05: NSC338258), was found 
by a combined screening and molecular modelling procedure.179 This compound directly 
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down-regulate c-MYC expression, using the same exon-specific assay.179 Use of a reporter 
assay with quadruplex-containing and quadruplex-negative constructs in the promoter can 
also provide evidence of promoter quadruplex involvement,180 although the approach by itself 
is less definitive than a genetic one. It has been used, for example, to study effects produced 
by disubstituted indolo[3,2-c]quinolines on k-RAS expression in colon cancer cells and their 
relationship to binding to the k-RAS promoter quadruplex,181 as well as with compounds 
targeting BCL-2 and c-KIT quadruplexes.168,174 
         The fluoroquinolone-based quadruplex-binding compound quarfloxin (21) (CX-3543: 
5-fluoro-N-(2-((S)-1-methylpyrrolidin-2-yl)ethyl)-3-oxo-6-((R)-3-(pyrazin-2-yl) pyrrolidin-
1-yl)-3H-benzo[b]pyrido[3,2,1-kl] phenoxazine-2-carboxamide)182,183 is an example of 
evolution in target considerations. It was originally developed as a c-MYC quadruplex 
stabiliser. Subsequent studies have indicated that it acts on ribosomal DNA (rDNA), which 
has a large number of putative quadruplex sequences, and then inhibits rDNA-nucleolin 
interactions, which in turn inhibits RNA polymerase I transcription.183 This compound 
associates with nucleolin in cancer cell nuclei and causes rRNA synthesis inhibition. It 
produced significant reductions in tumour volume in the MDA-MB-231 breast cancer and 
MIA-PACA-2 pancreatic cancer xenograft models. (21) is distinguished by being the first-in-
class, (and to date, only) quadruplex-binding compound to have entered clinical trials for 
human cancer. Phase 1 trials indicated good patient tolerance and a phase 2 trial was in 
carcinoid/neuroendocrine tumours, a tumour type for which the phase 1 trial indicated some 
responses. Compound (21) has more recently been licenced to Tetragene Inc 
(www.tetragene.com) in order for clinical development to continue. It will be interesting to 
see the application of next-generation sequencing technologies to determine the actual targets 
in the genome for this drug.  
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RNA QUADRUPLEXES 
     By contrast with promoter quadruplexes, the concept of quadruplex formation in mRNA 
sequences has the obvious attraction unwinding of duplex nucleic acid is not required.184 
Thus a given RNA G-tract sequence can more readily fold into a quadruplex form than a 
DNA duplex one. In addition, in vitro studies have indicated that RNA quadruplexes are 
more thermodynamically stable than their DNA counterparts185-187 and are less liable to 
conformational and topological heterogeneity, probably as a consequence of the additional 
hydrogen-bonding possibilities provided by the 2' sugar hydroxyl group in RNAs. The 
finding that quadruplex sequences are over-represented in the 5'-untranslated regions (5'-
UTR) of many human genes188,189 has catalysed interest in the category of sequences have 
been identified in a number of genes, for example, in BCL-2,190 n-RAS,191 the human 
estrogen receptor alpha,192 the MT3 matrix metalloproteinase,193 transforming growth factor 
β2194 and several oncogenes targeted by the cap-binding helicase eIF4A,195 as well as more 
generally in introns.196 There is good evidence that 5'-UTR quadruplexes are involved in 
post-translational gene regulation,197,198 although the exact role of a particular quadruplex 
depends on its locus within the 5'-UTR. The quadruplex antibody approach has been used to 
visualise the occurrence of RNA quadruplexes in human cells,199 which was enhanced when a 
RNA quadruplex-specific small molecule (a carboxy derivative of compound (1)) was used. 
134 
       Small-molecule targeting of 5'-UTR quadruplexes has been shown to inhibit translation, 
for example, with the N-RAS200 and TRF2198 genes, with observations of decreased levels of 
translation efficiency using in vitro reporter assays, using respectively pyridine-2,6-bis-
quinolino-dicarboxamide and bis-quinolinium derivatives. It has been shown201 that RNA 5'-
UTR quadruplexes can be targeted in cells, in a study with the K-RAS gene using the photo-
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activated porphyrin compound tri-meso(N-methyl-4-pyridyl), meso(N-tetradecyl-4-pyridyl) 
porphine. This compound has cytoplasmic rather than nuclear localisation. It down-regulates 
k-RAS protein levels in pancreatic cancer PANC-1 cells (which over-express this protein), by 
up to 80% in a dose-dependent manner, and also produces cell-growth arrest. These changes 
were found to be correlated with changes in mRNA levels. 
       There is much current interest in RNA quadruplexes formed from expansion of simple 
quadruplex motifs such as the hexanucleotide repeat r(G4C2). Such repeat expansions are 
found in a number of neurodegenerative diseases.202 The r(G4C2) motif occurs in the non-
coding region of the C9orf72 gene and is associated with the majority of cases of the 
neurodegenerative diseases amyotropic lateral sclerosis (ALS) and frontotemporal dementia 
(FDT).203 The repeats can form RNA quadruplexes204,205, which have been directly related to 
disease progression,204 although the exact mechanisms relating to C9orf72 quadruplexes are 
not known at present. It is not clear for example, whether stabilising the quadruplexes will 
result in beneficial changes in their association with RNA-binding proteins, or what effects 
this will have on the level of further truncated C9orf72 transcripts. A start has been made on 
developing small-molecule targeting of the C9orf72 quadruplex; initial experiments206 with 
the non-selective porphyrin compound (9) show that this ligand does bind to the C9orf72 
RNA quadruplex, which then inhibits binding of two established RNA binding proteins, 
hnRNPA1 and ASF/SF2 to the quadruplex. The C9orf72 repeat expansion RNA can also in 
principle form a hairpin arrangement in equilibrium with a quadruplex, with the latter 
favoured in K+ but not Na+-containing solution. It is not known what the effect on this would 
be in the crowded environment of the cytoplasm. A focussed library of 132 RNA-binding 
small molecules has been used to screen the C9orf72 RNA repeat in vitro.207 The three hit 
compounds were found to bind to the repeats in cells using a pull-down technique and had an 
effect not only on repeat translation but also on numbers of RNA foci in repeat-expressing 
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neurons. Two of the compounds have a curved shape resembling classic DNA minor groove 
binding compounds; the third, most biologically active compound is an ellipticine derivative 
with a single piperidine (cationic) side-chain (22). Remarkably, very few ellipticine 
derivatives have been evaluated for quadruplex binding and cellular activity, a notable 
exception being GQC-05 (NSC338258: 20), also with a single, though different side-chain, 
which down-regulates c-MYC expression.180      
QUADRUPLEXES IN REPLICATION 
      Quadruplexes can occur at many loci208-211 throughout the human and other genomes in 
addition to their well-documented presence in promoters, untranslated regions and telomeres. 
They are present in immunoglobulin switch regions and in breakpoint regions in many cancer 
genomes.212 They may well play a more general role in gene regulation213, consist with their 
well-documented non-random occurrence throughout the genome. Replication presents 
opportunities for DNA quadruplexes to be formed since DNA becomes unwound and 
transiently single-stranded. In principle their occurrence presents a stall to replication, but in 
practice such impediments are effectively resolved by, in particular helicases.214,215 However 
when helicases involved in replication and repair, such as Pif1216,217, FANCJ218,219 and the 
Bloom’s helicase are mutated,60,220, as is often the case in cancer cells, then replication is 
stalled. Quadruplex replication arrest (and the appearance of increased numbers of 
quadruplex foci in cells), is augmented by quadruplex-binding small molecules such as the 
polyoxazole compound (13),60 the resulting quadruplex complexes are more resistant to 
helicase unwinding than the native quadruplexes.221 The helicases XPB and XPD, which are 
associated with promoter activity and transcriptional regulation, also unwind quadruplexes.215 
The RTEL1 helicase unwinds and resolves quadruplexes at telomeres;222 it is mutated in a 
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number of human cancers223 although it is not known as yet whether these mutations result in 
impaired quadruplex unwinding. 
       Helicase malfunction then provides a further basis for the concept of quadruplex-targeted 
selectivity in many cancers, and a working hypothesis to explain the observations of selective 
cancer cell growth inhibition induced by quadruplex-binding small molecules in vitro and in 
vivo. Few systematic compound library screens have been reported to date based on the 
concept of their ability to stabilise quadruplexes against helicase unwinding, but these would 
be a useful addition to existing approaches, possibly using the recently-described rapid 
fluorescence-based helicase assay224, which has been validated with a number of well-
established quadruplex-binding compounds.  
      Structure-based approaches to finding new ligands may also be fruitful. The DEAH (Asp-
Glu-Ala-His) box RNA helicase binds to and unwinds quadruplexes with parallel topology. 
The 2D-NMR solution structure has been determined225 of the quadruplex-binding DEAH 
peptide bound to a parallel quadruplex. This shows the α-helical core of the peptide sitting on 
a G-quartet end-face of the quadruplex (Figure 3) in a manner reminiscent of the 
chromophores of typical quadruplex-binding ligands. Several basic peptide side-chains are 
associated with the quadruplex phosphate groups. Thus the structure reinforces the view that 
ligand planarity is not an essential requirement for quadruplex binding and suggests ways in 
which novel peptomimetic ligands could be engineered to interfere with helicase unwinding 
and bind with high specificity to a particular quadruplex. 
QUADRUPLEX STRUCTURES  
       Crystallographic and 2D-NMR structural studies have determined the detailed molecular 
structures of DNA and RNA quadruplexes from a variety of sources (reviewed in 35,36,226, 227). 
Intramolecular and intermolecular quadruplexes formed from human-derived sequences have 
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been studied in most detail, with the latter formed from two (bimolecular) strands. 
Quadruplexes with four (tetramolecular) or three separate strands are also possible. All show 
the common features of at least two G-quartets, stacked together with a right-handed twist 
and connected by loop sequences. Loops can be of several distinct types; diagonal, lateral (or 
edgewise), and propeller (or chain-reversal). The spaces between the four strands are termed 
grooves, analogous to those in duplex DNA and RNA, although by contrast with the two 
groove sin duplex structures, quadruplexes have four grooves. Groove dimensions are 
sensitive to the size and nature of the loops and to topology – the pattern of glycosidic angles 
plays an important role in defining overall groove width and depth. The differences in groove 
dimensions are import factors in enabling small molecules to differentiate between different 
quadruplexes. A given loop type is associated with a given set of strand directions for the two 
strands that it connects. These various possibilities give rise to a large number of possible 
folds (topologies), of which only a small number have been observed to date. The guanines 
forming each quartet arise from the short G-tracts; however when the tracts are of unequal 
length or loops themselves contain guanines, then more complex arrangements may be 
possible and can even dominate the overall topology.  
Telomeric quadruplexes. There has been considerable emphasis on structural studies of 
quadruplexes formed by human telomeric DNA sequences,228,229 assembled from the repeat 
d(TTAGGG), in particular on intramolecular quadruplexes containing four such repeats.230-235  
All comprise a core of stacked G-quartets assembled from the G-tracts in successive repeats, 
held together by d(TTA loops).  The structures themselves display a variety of folds.228,230-235 
2D-NMR studies in dilute solution in K+ ion environments have revealed several types of 
fold with anti-parallel strands, including (3+1) hybrid topologies (Figure 4) in which three of 
the four backbone strands are in one direction (ie parallel) and the fourth is in the opposite 
antiparallel direction.230-232 The precise nature of the flanking sequences appears to play a 
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role in stabilising one particular type over another. A single fold dominates in Na+ solution, 
with two lateral and one diagonal loop, so that two backbone orientations are in one direction 
and the other two are anti-parallel.228 By contrast, the crystal structures235 of a human 
telomeric intramolecular and a bimolecular quadruplex containing K+ ions shows all strands 
parallel in both structures and with all the loops necessarily being of the propeller type in 
order to achieve this strand orientation (Figure 1). There is continuing controversy as to 
which of these folds best represents the human intramolecular quadruplex in cellular 
environments; under crowding and high concentration conditions the parallel form is 
predominant236,237, consistent with it also being present in cells, whereas in more dilute K+-
containing solution the (3+1) forms may predominate.  
      Crystal structures of small-molecule human telomeric quadruplex complexes representing 
several diverse chemotypes are available238-244, with structural data available in the PDB. 
Structures for a number of naphthalene diimide intramolecular complexes239-241 have been 
determined (Figure 5), as well as with berberine,243 two mesoporphyrin complexes244 and the 
crystal structure of a bimolecular complexes with the trisubstituted acridine compound (6).238 
All of these structures have parallel-stranded quadruplexes, with the ligand chromophore 
bound on an external G-quartet face and side-chain substituents located in quadruplex 
grooves. In all instances the core structure, of three stacked G-quartets, is constant and 
essentially unchanged. Also to a first approximation the quadruplexes in these complexes are 
closely similar overall to the native structures. However there are significant variations in 
conformation of the propeller loops and groove dimensions, with evidence of ligand-related 
effects.245 Analysis of the structural data on several naphthalene diimide derivative 
complexes shows that loop conformations are most constrained within a series of closely-
related compounds, giving confidence to conservative in silico design studies based on such 
crystal structures. These crystal structures have also highlighted the role of groove-bound 
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water molecules in generating a network of water-mediated hydrogen bonds to the cationic 
side-chain substituents of the naphthalene diimides.  
      Only one NMR-determined structure in this category has been reported to date246, 
involving an analogue of the cyclic polyoxazole compound (13) with six oxazole rings 
together with two alkylamino side-chains (23), which impart aqueous solubility to the 
otherwise insoluble macrocycle core. A human telomeric DNA sequence was used, which 
forms a (3+1) hybrid fold in the native state.230,232 This topology is retained in the complex 
(Figure 6), with the macrocycle stacked on one end of the quadruplex. The macrocycle has a 
significant out-of-plane twist, which is reflected in the non-planarity of the G-quartet on 
which it is stacked, indicating that G-quartets can accommodate chemotypes with substantial 
non-planarity without compromising overall quadruplex stability. Overall stabilisation of the 
six oxazole rings arises from a number of close contacts to backbone and two sideways-on 
loop bases, which contribute to the preference for this particular topology. The two flexible 
side-chains are in close hydrogen-bond contact with backbone phosphate atoms. The overall 
structure provides some clear pointers to ways in which affinity and selectivity can be 
enhanced by rational modification of, in particular, the side-chains. 
      Small-molecule binding tends to favour a particular quadruplex topology, dependent on 
the precise nature of the ligand, which can be reliably assessed, at least for telomeric 
quadruplexes, by CD spectroscopy.247 Thus compound (13) and the pentacyclic acridines 
derivative (10), which has minimal substituents, both have a preference for anti-parallel type 
quadruplexes whereas the porphyrin (9) and a number of porphyrin derivatives as well as 
tetrasubstituted naphthalene diimide compounds, prefer the parallel fold. This behaviour has 
been rationalised on the basis of the available surface area at the chromophore binding site, 
the 3' or 5' terminal G-quartet.248 
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     Human telomeric RNA sequences can also readily form quadruplexes. However unlike 
their DNA counterparts, these are altogether more conformationally rigid and fold into only a 
single topology in K+ solution. This is the all-parallel-stranded form, observed both in the 
crystal249 and in dilute solution by 2D-NMR;250 both structures are closely similar to the 
crystal structures of the DNA telomeric quadruplex. The crystal structure has highlighted the 
role of the O2' ribose hydroxyl group in stabilising r(UUA) propeller loop conformation via 
hydrogen bonding.  Only one structure of an RNA telomeric quadruplex ligand complex is 
currently available, involving a disubstituted acridine chromophore having two 
amidoalkylamino side-chains.251 The r(UUA) propeller loops have altered conformations 
compared to the native structure, with the O2' ribose hydroxyl groups hydrogen bonding to 
loop adenine bases so that these bases swing round to become in-plane with the terminal G-
quartet of the quadruplex. The resulting extended r(AGGGGA) surface is able to 
accommodate two side-by-side bound ligand molecules.  
Promoter and other quadruplexes. 2D-NMR studies in particular have validated the 
existence of stable quadruplexes for a number of promoter quadruplex sequences. These are 
notable for their sequence diversity, and include structures for c-MYC,252,253 BCL-2,254,255 
VEGF
256, hTERT166 and RET257 quadruplexes, all of which have fully-assigned spectra and 
structures deposited in the PDB. Remarkably, the majority of the major species in solution 
tend to have parallel topology, which is a consequence of most sequences have at least one 
short (n<3 nucleotide) propeller loop, whose stereochemistry requires strands to be parallel; 
the VEGF 22-mer sequence d(CG4CG3CCG5CG4) is typical (Figure 7), with two single-
nucleotide dC loops and a longer tetranucleotide loop, which plays a role in overall 
stabilisation of this quadruplex. This parallel propensity is also shown, for example, by the 
RET oncogene quadruplex, with one single-nucleotide dC loop and two d(GCG) propeller 
loops. Examination of the prevalence of single nucleotides in the quadruplex surveys of the 
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human genome25,26 indicate that they probably comprise the majority of loop types in 
quadruplexes.  
     However the existence of propeller loops and of parallel strands does not necessarily lead 
to a simple all-parallel topology, if for example guanine bases occur within loop regions and 
also actively participate in quartet formation. This can result in an altogether more complex 
fold. An example is one of the two sequences in the c-KIT promoter, which has been 
extensively characterised by 2D-NMR42 and by X-ray crystallography.43,44 A non-G-tract 
guanosine situated between two cytosine loops, is folded back and forms part of the G-quartet 
core. This overall fold has not been observed in other quadruplexes, which is unsurprising 
given that the primary 22-mer sequence has a unique occurrence in the human genome.256 
The c-KIT fold (Figure 8) is conserved between solution and crystal, providing further 
support for the notion that the topology of quadruplexes with parallel strands is likely to be 
conformationally stable. 
     No crystal structures of small molecule complexes with non-telomeric DNA quadruplexes 
have been reported to date. Three 2D-NMR structures of c-MYC promoter quadruplexes have 
been determined, with the porphyrin compound (9)259, the (bisquinolinium) phenanthroline 
compound260 Phen-DC3 (24) and a crescent-shaped mono-substituted quindoline compound 
with an aminoalkylamino side-chain.261 The chromophores in all three structures are stacked 
over a terminal G-quartet of the quadruplex core. The complex with compound (9) has the 
substituent N-methylpyridyl groups positioned close to the edges of the grooves but not 
actually bound in them. Unsurprisingly this compound has modest quadruplex selectivity, 
being able to also bind effectively to duplex nucleic acids. The quindoline substituents of 
compound (24) have extensive overlap with the guanines of the terminal G-quartet (Figure 9) 
whereas the overall crescent-like shape of the molecule ensures that it would stack only 
poorly in a duplex intercalation site (Figure 10), in accord with its high quadruplex 
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selectivity. The NMR structure rationalises earlier data, on for example, analogues with 
pyridinium rings replacing the quinolones, which have reduced quadruplex-stabilising ability. 
It also suggests sites of functionalisation to enhance affinity and selectivity. The mono-
substituted quindoline 2: 1 complex261 is unusual in that a ligand molecule is bound to each 
terminal G-quartet face, with additional stabilisation from 5' and 3' flanking nucleotides. The 
short protonated aminoalkylamino side-chain attached to the quindoline skeleton is barely 
able to reach the nearest groove (Figure 11), suggesting ways in which to improve affinity, as 
well as selectivity for this particular quadruplex.  
     There are remarkably few detailed molecular structures available for RNA quadruplexes 
and none to date of 5'-UTR ones. Those determined include several in more complex flanking 
sequence environments than those in the structures of simple isolated DNA quadruplexes. An 
RNA quadruplex is the target of the Fragile X Mental Retardation Protein (FMRP) and a co-
crystal structure262 (Figure 12) shows recognition of this quadruplex by the arginine-glycine-
rich (RGG) motif of the protein. This quadruplex is at the end of a helical RNA stem, where 
the RGG β-turn is bound. There is an extensive pattern amino-acid contacts to the RNA, 
stabilising the interface and its mixed-base quartet. As with the DEAH-box helicase, one sees 
a protein motif bound at one end of the quadruplex, analogous to small-molecule binding 
sites, and suggesting where small-molecule inhibitors might best act. Two co-crystal 
structures263,264 of small-molecule fluorophores bound to a novel RNA quadruplex aptamer 
have revealed an unprecedented quadruplex fold with, in both structures, just two G-quartets. 
This parallel-stranded quadruplex is formed at the junction between two RNA duplex stems, 
with the strands folding back and each donating guanines to the quartets. The sequences 
involved do not obviously conform to the quadruplex rules and there are no G-tracts of more 
than two nucleotides in length. The two fluorophores are closely-related - in one structure264 it 
is 3,5-difluoro-4-hydroxybenzylidene imidazolinone (25) - both are bound in a stacking 
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environment between one G-quartet and the adjacent base triplet (Figure 13), which are both 
part of an extended co-planar run of duplex and quadruplex base pairs, triplets and quartets. 
There are a number of contacts involving 2'-ribose hydroxyl atoms and fluorophore. 
Altogether these structures show that quadruplexes, perhaps RNA ones in particular, can 
form highly specific small-molecule binding environments, especially when part of more 
extensive nucleic acid structures.    
QUADRUPLEX SELECTIVITY 
     Can small molecules have (i) selectivity for quadruplexes over duplex and other nucleic 
acids forms, and (ii) selectivity for a particular quadruplex? The first question is 
straightforward to answer, in the affirmative. There are many examples in the literature of 
individual compounds, and of broad chemotypes that have low or minimal affinity for duplex 
nucleic acids as well as high quadruplex affinity (this is typically assessed on a small number 
of quadruplex types). Heteroaromatic polycyclic compounds such as substituted acridines, 
quindolines, ellipticines and naphthalene-diimides, tend to show promiscuous binding to 
various types of nucleic acid structure; selectivity for the larger surface area of a terminal G-
quartet increases with ligand size and especially with the number of side-chain substituents. 
This however is at the cost of reduced drug-like character - higher molecular weight and 
increased cationic charge, even though several of these compounds are showing anticancer 
effects in vivo. Many macrocyclic and crescent-shape molecules on the other hand, have 
built-in low duplex-binding ability by virtue of their inability to effectively bind into a duplex 
intercalation site (see Figure 10). These crescent-shaped molecules bear some resemblance to 
classic DNA duplex groove binders but crucially they do not have the shallow curvature 
characteristic of this class, with the three sides of the crescent being much more acutely 
angled in order to achieve selectivity. Examples include quindoline compounds261 and a 
Page 32 of 93
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
33 
 
number of oligo-oxazole-based compounds and several low-molecular weight meta-
substituted diphenyl furans.266  
        Selectivity for a particular quadruplex has generally been approached empirically rather 
than by exploiting the available structural data. Even so, screening approaches have resulted 
in several remarkable findings. For example the crescent-shaped heptacyclic compound 
TOxaPy, comprising four oxazole and three pyridyl rings (26) is highly selective267 for the 
Na+ form of the human telomeric quadruplex and binds only very weakly to any of the K+ 
forms,229-235 indicating a marked topological preference for the antiparallel Na+ form.228 
Compound (26) also shows some affinity for several promoter quadruplexes. Selectivity for 
human telomeric quadruplex DNA can in principle be enhanced by exploiting the potential of 
the 3' single-stranded telomeric DNA overhang to form tandem quadruplexes, analogous to 
‘beads on a string.’268 Such selectivity has been found269 with a hybrid oxazole-triazole 
compound, which can have a crescent-shaped conformation. The goal of designing small 
molecules selective for particular promoter quadruplexes is altogether more challenging and 
no studies have been reported to date utilising the available structural data. Screening 
methods continue to be employed, with some successes. For example, several members of a 
series of crescent-shaped bis(benzimidazole)-phenanthroline compounds, with additional 
flexible alkylamino side-chains have been found to be selective for the c-MYC and c-KIT 
promoter quadruplexes over a human telomeric one and duplex DNA.270 These findings have 
been rationalised by molecular dynamics simulations, which emphasise the role of the side-
chains in propeller loop recognition. An innovative application of small-molecule 
microarrays, screening 20,000 compounds, has been used to find a selective c-MYC promoter 
quadruplex inhibitor.271 The lead compound from this approach, a disubstituted benzofuran 
derivative (27), does not have the characteristics of a conventional quadruplex binder and 
produces only a modest increase in c-MYC quadruplex melting temperature (∆Tm), of 2.1° C. 
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On the other hand, measurement of binding affinity by surface plasmon resonance (SPR) 
gave a low µM value for Kd, sufficient to elicit a biological response. Significantly, SPR 
measurements on five other promoter quadruplexes did not record binding, although weak 
binding was found with two others (from the BCL-2 and RB1 genes). In accord with this 
selectivity, an exon-specific assay179 using the Burkitt’s lymphoma cell line CA46, 
demonstrated that effects were ascribable to binding to the c-MYC promoter quadruplex 
locus. Studies on various panels of cancer cell lines has confirmed and extended these finding 
of high selectivity, so that overall this represents the first detailed proof of concept study in 
this field. The lead compound (27), while not being an ideal drug candidate, is an appropriate 
starting-point for further optimisation. 
LIGAND DESIGN 
      The overwhelming majority of current quadruplex-binding small molecule scaffolds80, 
109,265,272 have been selected on the basis of the simple premise of possessing102-104 (i) a 
heteropolyaromatic planar chromophore, which binds via π-π stacking to a terminal G-
quartet, and (ii) one or more flexible substituents with a cationic charge, to bind in 
quadruplex grooves and to loops. Notable exceptions to these broad guidelines are (i) cationic 
porphyrin and related scaffolds, of which the best-studied is the tetra-N-methyl-pyridyl 
porphyrin, compound (9), and (ii) a number of ligand families, all characterised by having 
macrocyclic or crescent-shaped scaffolds. These scaffolds are mostly based on or derived 
from the telomestatin and related oxazole-linked macrocyclic chemotypes. Appropriate 
crescent shapes can be achieved using pyridyl or phenanthroline rings disubstituted with 
heteroaromatic groups such as quinolines. Members of both of these broad classes of 
compounds bind to the terminal G-quartets in telomeric and other quadruplexes, with 
sufficient affinity from π-π aromatic G-quartet stacking so to not require the involvement of 
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additional cationic groove-binding substituents. These quadruplex binders tend to have 
greater quadruplex selectivity over duplex DNA or RNA than those based on 
polyheteroaromatic chemotypes. 
      New quadruplex-binding chemotypes have mostly been found as outcomes of screening 
chemical libraries against a measurement of quadruplex affinity or stabilisation. We are now 
seeing the increasing use of much larger compound libraries, which is starting to move the 
field away from the established concepts of what constitutes a good quadruplex-binding 
ligand, and promises to ensure the development in time of altogether more drug-like 
chemotypes. Also in silico and structure-based approaches are being used with increasingly 
broader ranges of scaffolds. The extensive structural knowledge base for the various 
topological folds of the human telomeric monomeric quadruplex has prompted a number of 
in silico studies273-277 using, for the most part, well-established docking software with the 
crystallographic or NMR-derived structures. As well as the well-documented pitfalls of the 
approach in general, telomeric quadruplexes present several particular challenges as in silico 
targets:  
(i) the flexibility of the loops in these structures has rarely been taken into account,278 so 
“hits” from screening of small-molecule libraries can only be taken as indicative of plausible 
high-affinity hits and are generally not reliably predictive of ranking order. A survey245 of 
known crystal structures of telomeric quadruplex complexes with small molecules has found 
that a number of distinct loop types are represented in this data set, although one type does 
predominate. There appears to be a dependence of loop type on the nature of the small 
molecule, although at present it is not possible to predict this. A combined spectroscopic and 
molecular dynamics simulation study has shown that natural mutations in loop sequences 
may affect loop conformations and even overall quadruplex topology.279 This may be of 
especial relevance to the design of ligands specific to such mutated quadruplexes as further 
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sequence data on mutations in promoter regions becomes available, following the findings of 
hTERT promoter mutations in melanoma and other cancers.165 
(ii) In general in silico studies have taken a particular telomeric quadruplex topology as a 
starting-point. It cannot be assumed that the chosen topology is preferentially stabilised by 
the resulting hits, especially since some ligands are known to alter topology, for example 
from anti-parallel to parallel. 
(iii) in silico methods work best with well-defined binding pockets for example in nucleotide 
binding sites in kinases, which are not present in most structurally simple quadruplexes. No 
studies to date have been reported on in silico screening of more complex quadruplexes, 
where fragment-based approaches could also be used.       
        In spite of these caveats, it is apparent that the approach can successfully generate novel 
hits, and has the advantage of targeting quadruplex grooves as well as the more conventional 
terminal G-quartets. This has resulted in the discovery of a number of non-planar quadruplex-
binding compounds, some of which have the potential to be developed into drug-like 
leads.274-277 Docking studies have used a range of large in silico libraries, with the ZINC and 
ChemBridge databases employed, for example, to find hits against the c-MYC 
quadruplexes.280,281 Fragment-based design has not yet been used to full develop a novel lead 
compound, although a study using a fragment library derived from RNA-targeting has 
identified the potential of this approach.282 
     Data from X-ray crystallography35 and 2D-NMR studies36 on molecular structures of 
small-molecule quadruplex complexes, notably of telomeric quadruplexes has provided the 
starting-points for some of these in silico studies. The perennial question of the relevance of 
quasi-solid-state crystal structures to solution or even cellular conditions, is of especial 
significance for quadruplexes, since some do have folds that are environment-sensitive. 
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These crystal structures are densely packed and crowded solvent-containing environments 
akin to the cellular conditions surrounding nuclear DNA – it is notable that quadruplexes 
have been recently reported to be localised in the highly organised DNA of 
heterochromatin.135 It is therefore unsurprising that in the case of human telomeric 
quadruplexes - the most contentious category – studies of topology in crowded solution have 
mostly concurred with the crystal data. Water molecules can also play a more detailed, active 
and intimate role in ligand binding. The crystal structures, for example of several 
naphthalenediimide-telomeric quadruplex complexes,240,241 have revealed the consistent role 
of bridging water molecules in the grooves via hydrogen bonds between cationic groups at 
the termini of ligand side-chains, and phosphate groups lining the walls of the grooves.  
       Although those crystal structures have not been used directly for the design of new leads, 
they have been useful starting-points for structure-based optimisation of existing 
compounds.239 Recent 2D-NMR structures of quadruplex complexes also provide 
opportunities for ligand refinement and improvement.283 An important future application of 
this structural information, especially for polycyclic compounds, will be to enhance their 
drug-like features.  
Limitations of current quadruplex models. There are several potential challenges with the 
current approaches to measuring quadruplex-small molecule binding, which is normally 
assessed in vitro by one or more biophysical methods, using an isolated quadruplex as target. 
In particular there has been relatively little attention paid to the relationship of the behaviour 
and ligand binding of an isolated quadruplex, to its behaviour in its (DNA or RNA plus 
associated proteins) biological or cellular context. The higher-order telomeric quadruplexes 
arrangements possible in the single-stranded 3' overhang at the extreme end of eukaryotic 
telomeres are obvious and accessible ones to focus on, as discussed earlier in this review. The 
junctions of telomeric quadruplexes with duplex DNA may also be plausible ligand targets, 
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with ligand binding onto a d(TAT) base triplet platform formed at the junction.284 Analogous 
junctions may be formed around promoter DNA quadruplexes and have been observed in two 
extended RNA quadruplex-small molecule complexes.263,264 The sequences of the junctions 
and flanking regions may affect quadruplex topology. mRNA quadruplexes are also in 
principle susceptible to flanking and bystander effects, although the additional ribose 2'-OH 
groups may reduce flexibility and hence hinder topological change in RNA quadruplexes – 
this reduced flexibility has been noted in telomeric RNA quadruplexes which do not have the 
variability observed in dilute solution with their DNA counterparts.  
Quadruplex selectivity: a real or apparent problem? This review has highlighted those 
studies where individual small molecule leads and starting-points have been exemplified into 
chemical libraries, and from these structure-activity relationships have been evaluated, for 
example correlating quadruplex stabilisation measured by thermal shift (∆Tm) with 
telomerase inhibitory activity or changes in expression of a target gene. In reality, selectivity 
for individual quadruplexes has until recently been almost entirely the result of serendipitous 
discovery, following screening with either an individual pre-chosen quadruplex, or from a 
small library of (normally) promoter quadruplexes. Once a particular quadruplex has been 
chosen, affinity can be optimised on the basis of structure-activity relationships. Remarkably 
few studies have surveyed a complete genome, for example by whole-genome expression 
profiling285, to verify that the chosen quadruplex is in reality a significant biological target. 
We have discussed in an earlier section the advisability of being able to distinguish between 
direct effects arising from quadruplex-small molecule binding and consequential changes in 
the target gene’s expression, from effects that are in reality just correlated together and are 
not direct cause-and-effect. This latter circumstance can occur when other upstream 
components of a pathway, or of an intersecting pathway, are the direct targets and these may 
or may not be quadruplex-related. 
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        The task of specifically targeting an individual quadruplex in say the human genome 
appears at first sight to be an impossibly daunting one, unless that quadruplex has features so 
distinctive for structure-based design or library screening. This may be more realistic with 
very small genomes such as the HIV one, where all the potential quadruplexes can be 
identified. At present this approach is not obviously feasible for the human genome. 
Bioinformatics surveys of both DNA and RNA human quadruplexes have shown that the 
majority probably have at least one short loop, suggestive of a “simple” parallel topology. 
Many genomic quadruplexes are therefore likely to have the same general features, ie a core 
of stacked quartets with the loops forming four grooves. Structural and molecular dynamics 
data has shown that the groove dimensions and loop conformations are not fixed, but have 
significant flexibility, which will change on ligand binding. Even so, it is possible to 
categorise a large number of these simple quadruplexes into a few structural families. More 
complexes quadruplexes are formed, for example when the loops themselves contain guanine 
residues that can actively participate in core quartet formation via insertion, when a loop is of 
sufficient length to form its own stable secondary structure, or when the quadruplex is an 
RNA one. One of the c-KIT quadruplexes illustrates this, with both an insertion loop and a 
secondary structure loop, which results in a topology that has not been observed to date in 
any other quadruplex. Thus such instances may provide individual quadruplex starting-points 
for highly selective ligand design. It might be thought then that attempting to target a simple 
quadruplex with more generic structural features, is unlikely to be successful. This is belied 
by the recent success with a microarray compound library approach to targeting the c-MYC 
quadruplex.271 Even though the lead compound was only evaluated for selectivity with a 
small number of other quadruplexes (and therefore its genomic quadruplex selectivity is 
unknown), the fact that it was able to down-regulate c-MYC expression in a cancer cell with 
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some potency, demonstrates that the cell is in effect able to sort out selectivity, provided that 
the target plays a major role in maintaining the cell’s malignant phenotype.    
      Although targeting a single defined quadruplex within a genome may not be readily 
feasible at present, it is important to achieve high selectivity over binding to duplex DNA and 
RNA. Competition studies that examine (for example thermal stability (∆Tm)) effects of a 
ligand on a quadruplex in the presence of large excess of duplex DNA are valuable in that 
they have relevance to the nucleic acid biological context. Duplex nucleic acid affinity leads 
to non-specific cell toxicity; the fact that many quadruplex-binding small molecules have 
features that at first sight resemble, in particular, classic intercalative compounds, with 
implications of such off-target toxicity, should not deter further studies on them. It is notable 
that most of the quadruplex-binding compounds with reported anti-cancer activity in 
xenograft models, are based on classic polycyclic heteroaromatic cores, notably compounds 
(6),89 (10)128,286,, (16),168 (21)181 and EMICORON (N,N-bis[2-(1-piperidino)-ethyl]-1-(1-
piperidinyl)-6-[2-(1-piperidino)-ethyl]-benzo[ghi] perylene-3,4:9,10-tetracarboxylic 
diimide.287 This suggests that even if their genomic quadruplex selectivity is modest, it is 
sufficient to down-regulate key oncogenic targets. 
         Is it therefore necessary in practice to be confident that a single gene is being targeted at 
the promoter or UTR level by a small molecule? The experience of cancer therapeutics over 
the past 25 years suggests that in reality this does not matter as long as one can be confident 
of among the major quadruplex targets is a driver gene or genes that play a key role in the 
maintenance and progression of a particular cancer cell type. The oncogene addiction 
hypothesis288,289 states that some cancers rely on the dominant action of an individual 
oncogene for growth and viability, and that these are appropriate targets. In principle, then 
targeting aberrant telomere maintenance, promoter or 5'-UTR quadruplexes may be a fruitful 
way of demonstrating the importance of this hypothesis, and arriving at novel drugs for the 
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treatment of human cancers. The quadruplex approach holds out the promise of 
circumventing the challenges of targeting “undruggable” targets such as c-MYC and RAS at 
the protein level. The next few years will determine whether this promise becomes a reality 
as chemical-based approaches are increasingly combined with new biological tools in order 
to interfere with quadruplex function. 
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Figure legends 
Figure 1  
a. Stick representation of a guanine G-quartet, with hydrogen bonds shown as dashed 
lines. A potassium ion at the centre of the quartet is also shown. This is coordinated to 
O6 atoms of the quartet and also to those of the stacked adjacent quartet.   
b. Representation of the assembly of an intramolecular quadruplex from a human 
telomeric DNA sequence (PDB id 1KF1)235, illustrating the donation of one guanine 
from each of the four G-tracts to form an individual G-quartet. Three quartets stack 
together to form this quadruplex, linked by propeller loops 
Figure 2  
a. Cartoon representation of a quadruplex (PDB id 1JPQ), with various features 
highlighted and labelled. The stack of four G-quartets constitute the quadruplex core. 
Guanine bases are coloured blue. The loops contain thymine bases, coloured cyan. 
b. View of the same quadruplex, now looking down onto the quartet plane.  
Figure 3 
A cartoon view of the DEAH helicase peptide-quadruplex complex, as determined by 2D-
NMR.225 The α-helix core of the peptide is shown sitting on an external G-quartet face (PDB 
id 2N21). 
Figure 4 
A view of a (3+1) hybrid human telomeric quadruplex, determined by 2D-NMR (PDB id 
2HY9).231 
Figure 5 
Page 79 of 93
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
80 
 
View showing the crystal structure241 of an intramolecular human telomeric DNA G-
quadruplex bound by the tetra-substituted naphthalene-diimide compound (16), shown in 
stick form (PDB id 3UYH). 
Figure 6 
Two orthogonal views of the 2D-NMR structure246 of a complex between a human telomeric 
quadruplex and a telomestatin analogue (23), shown in stick representation (PDB id 2MB3).  
Figure 7  
Cartoon view of the parallel quadruplex formed from a sequence in the human VEGF 
promoter (PDB id 2M27), determined by 2D-NMR.256 
Figure 8 
Cartoon view of the high-resolution crystal structure43 for a quadruplex formed from a 
sequence in the c-KIT promoter (PDB id 3QXR). 
Figure 9 
View of the 2D-NMR structure260 of a c-MYC promoter quadruplex, with bound 
(bisquinolinium) phenanthroline Phen-DC3 (PDB id 2MGN), projected onto the plane of the 
G-quartets. Note the extensive π-π overlap between the four guanines of the terminal quartet 
and the two quinolinium and phenanthroline moieties. 
Figure 10 
A molecular model for Phen-DC3 intercalated between two Watson-Crick base pairs in 
duplex DNA. Note that although the phenanthroline group is stacked between the base pairs, 
the two quinolinium groups are necessarily completely protruding into solvent and do not 
make any contacts with the DNA. 
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Figure 11 
View of the 2:1 complex between a mono-substituted quindoline compound261 (shown in 
stick representation) and a c-MYC promoter complex, determined by 2D-NMR (PDB id 
2L7V). 
Figure 12 
Co-crystal structure262 of the RNA quadruplex which is the target of the Fragile X Mental 
Retardation Protein (FMRP) bound to the arginine-glycine-rich (RGG) motif of the protein. 
The close-up view shows the part of the RNA stem and quadruplex, in cartoon form, together 
with the peptide (with the β-turn and backbone in cartoon form and side-chain atoms in stick 
form), bound onto a mixed quartet surface at one end of the quadruplex. 
Figure 13 
a. Close-up view of the crystal structure264 (PDB id 4Q9R) RNA quadruplex region of 
the RNA aptamer mimicking green fluorescent protein, bound to a substituted 
hydroxybenzylidene imidazolinone molecule (shown in space-filling mode).  
b. Close-up looking onto the plane of the G-quartets, showing the overlap between the 
bound hydroxybenzylidene imidazolinone molecule (in stick form) and the guanines. 
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